Home > > > Report Detail

Global Glioblastoma Multiforme Treatment (GBM) Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

Publisher Name :
Date: 09-Nov-2022
No. of pages: 138
Inquire Before Buying

Report Scope

This latest report researches the industry structure, revenue and gross margin. Major players' headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Glioblastoma Multiforme Treatment (GBM) companies, distributors, end users, industry associations, governments' industry bureaus, industry publications, industry experts, third party database, and our in-house databases.

This report also includes a discussion of the major players across each regional Glioblastoma Multiforme Treatment (GBM) market. Further, it explains the major drivers and regional dynamics of the global Glioblastoma Multiforme Treatment (GBM) market and current trends within the industry.

Key Companies Covered

In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:

- Merck

- Teva Pharmaceutical

- Arbor Pharmaceuticals

- Sun Pharmaceutical

- Roche

Market Segments

This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.

Glioblastoma Multiforme Treatment (GBM) Segment by Type

- Chemotherapy

- Radiotherapy

- Gene therapy

- Molecular biotechnology

Glioblastoma Multiforme Treatment (GBM) Segment by Application

- Hospital & Clinic

- ASCs

- Others

Key Regions & Countries

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.

- North America

- - United States

- - Canada

- Europe

- - Germany

- - France

- - UK

- - Italy

- - Russia

- - Nordic Countries

- - Rest of Europe

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - Southeast Asia

- - India

- - Australia

- - Rest of Asia

- Latin America

- - Mexico

- - Brazil

- - Rest of Latin America

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - UAE

- - Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Glioblastoma Multiforme Treatment (GBM) market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Report Includes:

This report presents an overview of global market for Glioblastoma Multiforme Treatment (GBM) market size. Analyses of the global market trends, with historic market revenue data for 2017 - 2021, estimates for 2022, and projections of CAGR through 2028.

This report researches the key producers of Glioblastoma Multiforme Treatment (GBM), also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Glioblastoma Multiforme Treatment (GBM), and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Glioblastoma Multiforme Treatment (GBM) revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Glioblastoma Multiforme Treatment (GBM) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Glioblastoma Multiforme Treatment (GBM) revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Merck, Teva Pharmaceutical, Arbor Pharmaceuticals, Sun Pharmaceutical and Roche, etc.

Global Glioblastoma Multiforme Treatment (GBM) Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Glioblastoma Multiforme Treatment (GBM) Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Chemotherapy
1.2.3 Radiotherapy
1.2.4 Gene therapy
1.2.5 Molecular biotechnology
1.3 Market by Application
1.3.1 Global Glioblastoma Multiforme Treatment (GBM) Market Growth Rate by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital & Clinic
1.3.3 ASCs
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Glioblastoma Multiforme Treatment (GBM) Market Size (2017-2028)
2.2 Glioblastoma Multiforme Treatment (GBM) Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028
2.3 Global Glioblastoma Multiforme Treatment (GBM) Market Size by Region (2017-2022)
2.4 Global Glioblastoma Multiforme Treatment (GBM) Market Size Forecast by Region (2023-2028)
2.5 Global Top Glioblastoma Multiforme Treatment (GBM) Countries Ranking by Market Size
3 Glioblastoma Multiforme Treatment (GBM) Competitive by Company
3.1 Global Glioblastoma Multiforme Treatment (GBM) Revenue by Players
3.1.1 Global Glioblastoma Multiforme Treatment (GBM) Revenue by Players (2017-2022)
3.1.2 Global Glioblastoma Multiforme Treatment (GBM) Market Share by Players (2017-2022)
3.2 Global Glioblastoma Multiforme Treatment (GBM) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Glioblastoma Multiforme Treatment (GBM) Revenue
3.4 Global Glioblastoma Multiforme Treatment (GBM) Market Concentration Ratio
3.4.1 Global Glioblastoma Multiforme Treatment (GBM) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Glioblastoma Multiforme Treatment (GBM) Revenue in 2021
3.5 Global Glioblastoma Multiforme Treatment (GBM) Key Players Head office and Area Served
3.6 Key Players Glioblastoma Multiforme Treatment (GBM) Product Solution and Service
3.7 Date of Enter into Glioblastoma Multiforme Treatment (GBM) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Glioblastoma Multiforme Treatment (GBM) Breakdown Data by Type
4.1 Global Glioblastoma Multiforme Treatment (GBM) Historic Revenue by Type (2017-2022)
4.2 Global Glioblastoma Multiforme Treatment (GBM) Forecasted Revenue by Type (2023-2028)
5 Global Glioblastoma Multiforme Treatment (GBM) Breakdown Data by Application
5.1 Global Glioblastoma Multiforme Treatment (GBM) Historic Market Size by Application (2017-2022)
5.2 Global Glioblastoma Multiforme Treatment (GBM) Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Glioblastoma Multiforme Treatment (GBM) Revenue by Company (2020-2022)
6.2 North America Glioblastoma Multiforme Treatment (GBM) Revenue by Type (2017-2028)
6.3 North America Glioblastoma Multiforme Treatment (GBM) Revenue by Application (2017-2028)
6.4 North America Glioblastoma Multiforme Treatment (GBM) Revenue by Country (2017-2028)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe Glioblastoma Multiforme Treatment (GBM) Revenue by Company (2020-2022)
7.2 Europe Glioblastoma Multiforme Treatment (GBM) Revenue by Type (2017-2028)
7.3 Europe Glioblastoma Multiforme Treatment (GBM) Revenue by Application (2017-2028)
7.4 Europe Glioblastoma Multiforme Treatment (GBM) Revenue by Country (2017-2028)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Glioblastoma Multiforme Treatment (GBM) Revenue by Company (2020-2022)
8.2 Asia Pacific Glioblastoma Multiforme Treatment (GBM) Revenue by Type (2017-2028)
8.3 Asia Pacific Glioblastoma Multiforme Treatment (GBM) Revenue by Application (2017-2028)
8.4 Asia Pacific Glioblastoma Multiforme Treatment (GBM) Revenue by Region (2017-2028)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Vietnam
9 Latin America
9.1 Latin America Glioblastoma Multiforme Treatment (GBM) Revenue by Company (2020-2022)
9.2 Latin America Glioblastoma Multiforme Treatment (GBM) Revenue by Type (2017-2028)
9.3 Latin America Glioblastoma Multiforme Treatment (GBM) Revenue by Application (2017-2028)
9.4 Latin America Glioblastoma Multiforme Treatment (GBM) Revenue by Country (2017-2028)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Glioblastoma Multiforme Treatment (GBM) Revenue by Company (2020-2022)
10.2 Middle East and Africa Glioblastoma Multiforme Treatment (GBM) Revenue by Type (2017-2028)
10.3 Middle East and Africa Glioblastoma Multiforme Treatment (GBM) Revenue by Application (2017-2028)
10.4 Middle East and Africa Glioblastoma Multiforme Treatment (GBM) Revenue by Country (2017-2028)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
11 Company Profiles
11.1 Merck
11.1.1 Merck Company Details
11.1.2 Merck Business Overview
11.1.3 Merck Glioblastoma Multiforme Treatment (GBM) Products and Services
11.1.4 Merck Glioblastoma Multiforme Treatment (GBM) Revenue in Glioblastoma Multiforme Treatment (GBM) Business (2017-2022)
11.1.5 Merck Glioblastoma Multiforme Treatment (GBM) SWOT Analysis
11.1.6 Merck Recent Developments
11.2 Teva Pharmaceutical
11.2.1 Teva Pharmaceutical Company Details
11.2.2 Teva Pharmaceutical Business Overview
11.2.3 Teva Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Products and Services
11.2.4 Teva Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Revenue in Glioblastoma Multiforme Treatment (GBM) Business (2017-2022)
11.2.5 Teva Pharmaceutical Glioblastoma Multiforme Treatment (GBM) SWOT Analysis
11.2.6 Teva Pharmaceutical Recent Developments
11.3 Arbor Pharmaceuticals
11.3.1 Arbor Pharmaceuticals Company Details
11.3.2 Arbor Pharmaceuticals Business Overview
11.3.3 Arbor Pharmaceuticals Glioblastoma Multiforme Treatment (GBM) Products and Services
11.3.4 Arbor Pharmaceuticals Glioblastoma Multiforme Treatment (GBM) Revenue in Glioblastoma Multiforme Treatment (GBM) Business (2017-2022)
11.3.5 Arbor Pharmaceuticals Glioblastoma Multiforme Treatment (GBM) SWOT Analysis
11.3.6 Arbor Pharmaceuticals Recent Developments
11.4 Sun Pharmaceutical
11.4.1 Sun Pharmaceutical Company Details
11.4.2 Sun Pharmaceutical Business Overview
11.4.3 Sun Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Products and Services
11.4.4 Sun Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Revenue in Glioblastoma Multiforme Treatment (GBM) Business (2017-2022)
11.4.5 Sun Pharmaceutical Glioblastoma Multiforme Treatment (GBM) SWOT Analysis
11.4.6 Sun Pharmaceutical Recent Developments
11.5 Roche
11.5.1 Roche Company Details
11.5.2 Roche Business Overview
11.5.3 Roche Glioblastoma Multiforme Treatment (GBM) Products and Services
11.5.4 Roche Glioblastoma Multiforme Treatment (GBM) Revenue in Glioblastoma Multiforme Treatment (GBM) Business (2017-2022)
11.5.5 Roche Glioblastoma Multiforme Treatment (GBM) SWOT Analysis
11.5.6 Roche Recent Developments
12 Glioblastoma Multiforme Treatment (GBM) Market Dynamics
12.1 Glioblastoma Multiforme Treatment (GBM) Market Trends
12.2 Glioblastoma Multiforme Treatment (GBM) Market Drivers
12.3 Glioblastoma Multiforme Treatment (GBM) Market Challenges
12.4 Glioblastoma Multiforme Treatment (GBM) Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
List of Tables
Table 1. Global Glioblastoma Multiforme Treatment (GBM) Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Chemotherapy
Table 3. Key Players of Radiotherapy
Table 4. Key Players of Gene therapy
Table 5. Key Players of Molecular biotechnology
Table 6. Global Glioblastoma Multiforme Treatment (GBM) Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 7. Global Glioblastoma Multiforme Treatment (GBM) Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028
Table 8. Global Glioblastoma Multiforme Treatment (GBM) Revenue by Region (2017-2022) & (US$ Million)
Table 9. Global Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Region (2017-2022)
Table 10. Global Glioblastoma Multiforme Treatment (GBM) Revenue by Players (2017-2022) & (US$ Million)
Table 11. Global Glioblastoma Multiforme Treatment (GBM) Market Share by Players (2017-2022)
Table 12. Global Top Glioblastoma Multiforme Treatment (GBM) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glioblastoma Multiforme Treatment (GBM) as of 2021)
Table 13. Ranking of Global Top Glioblastoma Multiforme Treatment (GBM) Companies by Revenue (US$ Million) in 2021
Table 14. Global 5 Largest Players Market Share by Glioblastoma Multiforme Treatment (GBM) Revenue (CR5 and HHI) & (2017-2022)
Table 15. Key Players Headquarters and Area Served
Table 16. Key Players Glioblastoma Multiforme Treatment (GBM) Product Solution and Service
Table 17. Date of Key Manufacturers Enter into Glioblastoma Multiforme Treatment (GBM) Market
Table 18. Mergers & Acquisitions, Expansion Plans
Table 19. Global Glioblastoma Multiforme Treatment (GBM) Market Size by Type (2017-2022) & (US$ Million)
Table 20. Global Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Type (2017-2022)
Table 21. Global Glioblastoma Multiforme Treatment (GBM) Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 22. Global Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Type (2023-2028)
Table 23. Global Glioblastoma Multiforme Treatment (GBM) Market Size by Application (2017-2022) & (US$ Million)
Table 24. Global Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Application (2017-2022)
Table 25. Global Glioblastoma Multiforme Treatment (GBM) Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 26. Global Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Application (2023-2028)
Table 27. North America Glioblastoma Multiforme Treatment (GBM) Revenue by Company (2020-2022) & (US$ Million)
Table 28. North America Glioblastoma Multiforme Treatment (GBM) Revenue by Type (2017-2022) & (US$ Million)
Table 29. North America Glioblastoma Multiforme Treatment (GBM) Revenue by Type (2023-2028) & (US$ Million)
Table 30. North America Glioblastoma Multiforme Treatment (GBM) Revenue by Application (2017-2022) & (US$ Million)
Table 31. North America Glioblastoma Multiforme Treatment (GBM) Revenue by Application (2023-2028) & (US$ Million)
Table 32. North America Glioblastoma Multiforme Treatment (GBM) Revenue by Country (2017-2022) & (US$ Million)
Table 33. North America Glioblastoma Multiforme Treatment (GBM) Revenue by Country (2023-2028) & (US$ Million)
Table 34. Europe Glioblastoma Multiforme Treatment (GBM) Revenue by Company (2020-2022) & (US$ Million)
Table 35. Europe Glioblastoma Multiforme Treatment (GBM) Revenue by Type (2017-2022) & (US$ Million)
Table 36. Europe Glioblastoma Multiforme Treatment (GBM) Revenue by Type (2023-2028) & (US$ Million)
Table 37. Europe Glioblastoma Multiforme Treatment (GBM) Revenue by Application (2017-2022) & (US$ Million)
Table 38. Europe Glioblastoma Multiforme Treatment (GBM) Revenue by Application (2023-2028) & (US$ Million)
Table 39. Europe Glioblastoma Multiforme Treatment (GBM) Revenue by Country (2017-2022) & (US$ Million)
Table 40. Europe Glioblastoma Multiforme Treatment (GBM) Revenue by Country (2023-2028) & (US$ Million)
Table 41. Asia Pacific Glioblastoma Multiforme Treatment (GBM) Revenue by Company (2020-2022) & (US$ Million)
Table 42. Asia Pacific Glioblastoma Multiforme Treatment (GBM) Revenue by Type (2017-2022) & (US$ Million)
Table 43. Asia Pacific Glioblastoma Multiforme Treatment (GBM) Revenue by Type (2023-2028) & (US$ Million)
Table 44. Asia Pacific Glioblastoma Multiforme Treatment (GBM) Revenue by Application (2017-2022) & (US$ Million)
Table 45. Asia Pacific Glioblastoma Multiforme Treatment (GBM) Revenue by Application (2023-2028) & (US$ Million)
Table 46. Asia Pacific Glioblastoma Multiforme Treatment (GBM) Revenue by Region (2017-2022) & (US$ Million)
Table 47. Asia Pacific Glioblastoma Multiforme Treatment (GBM) Revenue by Region (2023-2028) & (US$ Million)
Table 48. Latin America Glioblastoma Multiforme Treatment (GBM) Revenue by Company (2020-2022) & (US$ Million)
Table 49. Latin America Glioblastoma Multiforme Treatment (GBM) Revenue by Type (2017-2022) & (US$ Million)
Table 50. Latin America Glioblastoma Multiforme Treatment (GBM) Revenue by Type (2023-2028) & (US$ Million)
Table 51. Latin America Glioblastoma Multiforme Treatment (GBM) Revenue by Application (2017-2022) & (US$ Million)
Table 52. Latin America Glioblastoma Multiforme Treatment (GBM) Revenue by Application (2023-2028) & (US$ Million)
Table 53. Latin America Glioblastoma Multiforme Treatment (GBM) Revenue by Country (2017-2022) & (US$ Million)
Table 54. Latin America Glioblastoma Multiforme Treatment (GBM) Revenue by Country (2023-2028) & (US$ Million)
Table 55. Middle East and Africa Glioblastoma Multiforme Treatment (GBM) Revenue by Company (2020-2022) & (US$ Million)
Table 56. Middle East and Africa Glioblastoma Multiforme Treatment (GBM) Revenue by Type (2017-2022) & (US$ Million)
Table 57. Middle East and Africa Glioblastoma Multiforme Treatment (GBM) Revenue by Type (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Glioblastoma Multiforme Treatment (GBM) Revenue by Application (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Glioblastoma Multiforme Treatment (GBM) Revenue by Application (2023-2028) & (US$ Million)
Table 60. Middle East and Africa Glioblastoma Multiforme Treatment (GBM) Revenue by Country (2017-2022) & (US$ Million)
Table 61. Middle East and Africa Glioblastoma Multiforme Treatment (GBM) Revenue by Country (2023-2028) & (US$ Million)
Table 62. Merck Company Details
Table 63. Merck Business Overview
Table 64. Merck Glioblastoma Multiforme Treatment (GBM) Product and Services
Table 65. Merck Glioblastoma Multiforme Treatment (GBM) Revenue in Glioblastoma Multiforme Treatment (GBM) Business (2017-2022) & (US$ Million)
Table 66. Merck Glioblastoma Multiforme Treatment (GBM) SWOT Analysis
Table 67. Merck Recent Developments
Table 68. Teva Pharmaceutical Company Details
Table 69. Teva Pharmaceutical Business Overview
Table 70. Teva Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Product and Services
Table 71. Teva Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Revenue in Glioblastoma Multiforme Treatment (GBM) Business (2017-2022) & (US$ Million)
Table 72. Teva Pharmaceutical Glioblastoma Multiforme Treatment (GBM) SWOT Analysis
Table 73. Teva Pharmaceutical Recent Developments
Table 74. Arbor Pharmaceuticals Company Details
Table 75. Arbor Pharmaceuticals Business Overview
Table 76. Arbor Pharmaceuticals Glioblastoma Multiforme Treatment (GBM) Product and Services
Table 77. Arbor Pharmaceuticals Glioblastoma Multiforme Treatment (GBM) Revenue in Glioblastoma Multiforme Treatment (GBM) Business (2017-2022) & (US$ Million)
Table 78. Arbor Pharmaceuticals Glioblastoma Multiforme Treatment (GBM) SWOT Analysis
Table 79. Arbor Pharmaceuticals Recent Developments
Table 80. Sun Pharmaceutical Company Details
Table 81. Sun Pharmaceutical Business Overview
Table 82. Sun Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Product and Services
Table 83. Sun Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Revenue in Glioblastoma Multiforme Treatment (GBM) Business (2017-2022) & (US$ Million)
Table 84. Sun Pharmaceutical Glioblastoma Multiforme Treatment (GBM) SWOT Analysis
Table 85. Sun Pharmaceutical Recent Developments
Table 86. Roche Company Details
Table 87. Roche Business Overview
Table 88. Roche Glioblastoma Multiforme Treatment (GBM) Product and Services
Table 89. Roche Glioblastoma Multiforme Treatment (GBM) Revenue in Glioblastoma Multiforme Treatment (GBM) Business (2017-2022) & (US$ Million)
Table 90. Roche Glioblastoma Multiforme Treatment (GBM) SWOT Analysis
Table 91. Roche Recent Developments
Table 92. Glioblastoma Multiforme Treatment (GBM) Market Trends
Table 93. Glioblastoma Multiforme Treatment (GBM) Market Drivers
Table 94. Glioblastoma Multiforme Treatment (GBM) Market Challenges
Table 95. Glioblastoma Multiforme Treatment (GBM) Market Restraints
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Glioblastoma Multiforme Treatment (GBM) Sales Market Share by Type: 2021 VS 2028
Figure 2. Chemotherapy Features
Figure 3. Radiotherapy Features
Figure 4. Gene therapy Features
Figure 5. Molecular biotechnology Features
Figure 6. Global Glioblastoma Multiforme Treatment (GBM) Sales Market Share by Application: 2021 VS 2028
Figure 7. Hospital & Clinic Case Studies
Figure 8. ASCs Case Studies
Figure 9. Others Case Studies
Figure 10. Glioblastoma Multiforme Treatment (GBM) Report Years Considered
Figure 11. Global Glioblastoma Multiforme Treatment (GBM) Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global Glioblastoma Multiforme Treatment (GBM) Market Size 2017-2028 (US$ Million)
Figure 13. Global Glioblastoma Multiforme Treatment (GBM) Market Size Market Share by Region: 2021 VS 2028
Figure 14. Global Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Region in 2017 VS 2022
Figure 15. Global Top 10 Glioblastoma Multiforme Treatment (GBM) Countries Ranking by Market Size (US$ Million) in 2021
Figure 16. Global Glioblastoma Multiforme Treatment (GBM) Market Share by Players in 2021
Figure 17. Global Top Glioblastoma Multiforme Treatment (GBM) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glioblastoma Multiforme Treatment (GBM) as of 2021)
Figure 18. The Top 10 and 5 Players Market Share by Glioblastoma Multiforme Treatment (GBM) Revenue in 2021
Figure 19. North America Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Company in 2021
Figure 20. North America Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Type (2017-2028)
Figure 21. North America Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Application (2017-2028)
Figure 22. North America Glioblastoma Multiforme Treatment (GBM) Revenue Share by Country (2017-2028)
Figure 23. U.S. Glioblastoma Multiforme Treatment (GBM) Revenue (2017-2028) & (US$ Million)
Figure 24. Canada Glioblastoma Multiforme Treatment (GBM) Revenue (2017-2028) & (US$ Million)
Figure 25. Europe Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Company in 2021
Figure 26. Europe Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Type (2017-2028)
Figure 27. Europe Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Application (2017-2028)
Figure 28. Europe Glioblastoma Multiforme Treatment (GBM) Revenue Share by Country (2017-2028)
Figure 29. Germany Glioblastoma Multiforme Treatment (GBM) Revenue (2017-2028) & (US$ Million)
Figure 30. France Glioblastoma Multiforme Treatment (GBM) Revenue (2017-2028) & (US$ Million)
Figure 31. U.K. Glioblastoma Multiforme Treatment (GBM) Revenue (2017-2028) & (US$ Million)
Figure 32. Italy Glioblastoma Multiforme Treatment (GBM) Revenue (2017-2028) & (US$ Million)
Figure 33. Russia Glioblastoma Multiforme Treatment (GBM) Revenue (2017-2028) & (US$ Million)
Figure 34. Asia Pacific Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Company in 2021
Figure 35. Asia Pacific Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Type (2017-2028)
Figure 36. Asia Pacific Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Application (2017-2028)
Figure 37. Asia Pacific Glioblastoma Multiforme Treatment (GBM) Revenue Share by Region (2017-2028)
Figure 38. China Glioblastoma Multiforme Treatment (GBM) Revenue (2017-2028) & (US$ Million)
Figure 39. Japan Glioblastoma Multiforme Treatment (GBM) Revenue (2017-2028) & (US$ Million)
Figure 40. South Korea Glioblastoma Multiforme Treatment (GBM) Revenue (2017-2028) & (US$ Million)
Figure 41. India Glioblastoma Multiforme Treatment (GBM) Revenue (2017-2028) & (US$ Million)
Figure 42. Australia Glioblastoma Multiforme Treatment (GBM) Revenue (2017-2028) & (US$ Million)
Figure 43. Taiwan Glioblastoma Multiforme Treatment (GBM) Revenue (2017-2028) & (US$ Million)
Figure 44. Indonesia Glioblastoma Multiforme Treatment (GBM) Revenue (2017-2028) & (US$ Million)
Figure 45. Thailand Glioblastoma Multiforme Treatment (GBM) Revenue (2017-2028) & (US$ Million)
Figure 46. Malaysia Glioblastoma Multiforme Treatment (GBM) Revenue (2017-2028) & (US$ Million)
Figure 47. Philippines Glioblastoma Multiforme Treatment (GBM) Revenue (2017-2028) & (US$ Million)
Figure 48. Vietnam Glioblastoma Multiforme Treatment (GBM) Revenue (2017-2028) & (US$ Million)
Figure 49. Latin America Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Company in 2021
Figure 50. Latin America Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Type (2017-2028)
Figure 51. Latin America Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Application (2017-2028)
Figure 52. Latin America Glioblastoma Multiforme Treatment (GBM) Revenue Share by Country (2017-2028)
Figure 53. Mexico Glioblastoma Multiforme Treatment (GBM) Revenue (2017-2028) & (US$ Million)
Figure 54. Brazil Glioblastoma Multiforme Treatment (GBM) Revenue (2017-2028) & (US$ Million)
Figure 55. Argentina Glioblastoma Multiforme Treatment (GBM) Revenue (2017-2028) & (US$ Million)
Figure 56. Middle East and Africa Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Company in 2021
Figure 57. Middle East and Africa Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Type (2017-2028)
Figure 58. Middle East and Africa Glioblastoma Multiforme Treatment (GBM) Revenue Market Share by Application (2017-2028)
Figure 59. Middle East and Africa Glioblastoma Multiforme Treatment (GBM) Revenue Share by Country (2017-2028)
Figure 60. Turkey Glioblastoma Multiforme Treatment (GBM) Revenue (2017-2028) & (US$ Million)
Figure 61. Saudi Arabia Glioblastoma Multiforme Treatment (GBM) Revenue (2017-2028) & (US$ Million)
Figure 62. UAE Glioblastoma Multiforme Treatment (GBM) Revenue (2017-2028) & (US$ Million)
Figure 63. Merck Revenue Growth Rate in Glioblastoma Multiforme Treatment (GBM) Business (2017-2022)
Figure 64. Teva Pharmaceutical Revenue Growth Rate in Glioblastoma Multiforme Treatment (GBM) Business (2017-2022)
Figure 65. Arbor Pharmaceuticals Revenue Growth Rate in Glioblastoma Multiforme Treatment (GBM) Business (2017-2022)
Figure 66. Sun Pharmaceutical Revenue Growth Rate in Glioblastoma Multiforme Treatment (GBM) Business (2017-2022)
Figure 67. Roche Revenue Growth Rate in Glioblastoma Multiforme Treatment (GBM) Business (2017-2022)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
  • Global Nuclear Medicine Cyclotron Systems Market Report, History and Forecast 2018-2029
    Published: 11-Jan-2024        Price: US 3350 Onwards        Pages: 118
    The global Nuclear Medicine Cyclotron Systems market was valued at US$ 220.85 million in 2022 and will reach US$ 283.75 million by the end of 2029, growing at a CAGR of 4.38% during 2023-2029. Asia-Pacific market for Nuclear Medicine Cyclotron Systems was valued at $ 61.16 million in 2022 and will reach $ 104.22 million by 2029, at a CAGR of 5.84% during the forecast period of 2023 through 2029. Report Scope This report aims to provide a comprehensive presentation of the glo......
  • Global Non-imaging Diagnostic Catheter Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 95
    The global Non-imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Imaging Diagnostic Catheter Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 90
    The global Imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated......
  • Global PCR Equipment Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 77
    The global PCR Equipment market was valued at US$ 806 million in 2023 and is anticipated to reach US$ 1230.7 million by 2030, witnessing a CAGR of 6.7% during The forecast period 2024-2030. PCR (Polymerase Chain Reaction) equipment is widely used in molecular biology and genetics research for amplifying DNA and RNA sequences. The market for PCR equipment is influenced by several key drivers. Here are some of The significant market drivers: Advancements in Research and Diagnost......
  • Global Disposable Sterile Syringes and Needles Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 109
    The global Disposable Sterile Syringes and Needles market was valued at US$ 404.4 million in 2023 and is anticipated to reach US$ 539.1 million by 2030, witnessing a CAGR of 2.1% during The forecast period 2024-2030. North American market for Disposable Sterile Syringes and Needles is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Disposable Sterile Syringes and N......
  • Global Orthopaedic Power Tools Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Orthopaedic Power Tools market was valued at US$ 463.3 million in 2023 and is anticipated to reach US$ 746.5 million by 2030, witnessing a CAGR of 7.3% during The forecast period 2024-2030. North American market for Orthopaedic Power Tools is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Orthopaedic Power Tools is estimated to increase from $ million i......
  • Global Cerebrospinal Fluid Management Devices Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Cerebrospinal Fluid Management Devices market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Cerebrospinal Fluid Management Devices is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Cerebrospinal Fluid Management Devices is estimate......
  • Global CAD & CAM Milling Burs Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 79
    The global CAD & CAM Milling Burs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ ......
  • Global Artificial Teeth Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 98
    The global Artificial Teeth market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, a......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs